Pharmaceutically elegant, topical anhydrous aerosol foam

Details for Australian Patent Application No. 2005285441 (hide)

International Classifications

Event Publications

18 January 2007 PCT application entered the National Phase

PCT publication WO2006/031271 Priority application(s): WO2006/031271

29 April 2010 Application Accepted

Published as AU-B-2005285441

26 August 2010 Standard Patent Sealed

7 July 2011 Application for Amendment

The nature of the amendment is: Amend the name of the inventor to read Jones, David P.; Shah, Bhavesh P. and Aust, Duncan T.. Address for service in Australia - Pizzeys Patent and Trade Mark Attorneys Level 20 324 Queen Street Brisbane QLD 4000 2005297570 3,6-substituted 5-arylamino-1h-pyidine-2-one derivatives and related compounds as poly(ADP-ribose)polymerase (PARP) inhibitors in the treatment of tissue damage or disease caused by necrosis or apoptosis Sanofi-Aventis Deutschland GmbH The nature of the am

3 November 2011 Amendment Made

The nature of the amendment is: Amend the name of the inventor to read Jones, David P.; Shah, Bhavesh P. and Aust, Duncan T.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.